From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome
On May 29, 2020, Allyson Berent will discuss the journey that led her to becoming chief science officer of the largest research funding foundation for Angelman syndrome in the world (Foundation for Angelman Syndrome Therapeutics [FAST]), and the cofounder and chief operating officer of GeneTx Biotherapeutics — a biotech company solely focused on developing an antisense oligonucleotide for the treatment of Angelman syndrome — after her daughter was diagnosed with Angelman syndrome at 5.5 months old.
On 3 December 2014, Karen E. Adolph discussed how infants learn to generate and control their movements by adapting to environmental and social factors.
On 29 October 2014, Dan Littman described how intestinal bacteria affect immune system cell functioning, potentially contributing to systemic inflammation and autism.
On 23 September 2014, Nancy Kanwisher discussed the functional architecture of the social brain as an avenue for considering which functions are affected and which are preserved in autism.
On 23 April 2014, Gail Mandel presented the complex pathology of Rett syndrome.
On 26 March 2014, Ami Klin presented two new infant and toddler behavioral measures of social behaviors.
Director, Autism BrainNet
On 26 February 2014, David Amaral discussed different types of altered brain development among children with autism.